Sequana Medical announces 2023 Full Year Results and 2024 Outlook
March 28, 2024 03:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET alfapump® – PMA1 submitted to US FDA and accepted for substantive review, extensive feedback just received from...
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
March 26, 2024 02:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION26 March 2024, 07:00 a.m. CET Ghent, Belgium, 26 March 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
March 25, 2024 02:00 ET
|
Sequana Medical NV
MOJAVE – US Phase 1/2a study of DSR 2.0 for treatment of heart failure Previously reported strong data maintained after three-months follow-up: Diuretic response remained nearly normalized, with a...
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT
March 21, 2024 02:00 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND PROVIDES TRADING UPDATE
March 20, 2024 11:20 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
February 28, 2024 01:00 ET
|
Sequana Medical NV
Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024 Ghent, Belgium – 28 February 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...
SEQUANA MEDICAL ANNOUNCES EUR 3.0 MILLION CONVERTIBLE FINANCING FROM MAJOR SHAREHOLDERS AND AGREEMENT WITH LENDERS ON DEFERRAL OF DEBT SERVICE PAYMENTS
February 08, 2024 01:00 ET
|
Sequana Medical NV
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED...
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
January 29, 2024 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Acceptance and filing review is a first step in the PMA review process Indicates PMA application is sufficiently complete for in-depth review Received in advance of anticipated...
Transparency Notifications from Shareholders
January 24, 2024 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 24 January 2024, 06:00 pm CET Ghent, Belgium – 24 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in...
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
January 23, 2024 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET DSMBi rates DSR 2.0 as safe following review of data from non-randomized cohortData from non-randomized cohort...